According to FutureWise analysis the market for Alcoholic Hepatitis Therapeutics was estimated to be US$ 0.83 billion in 2023 and is expected reach US$ 1.21 billion in 2031 at a CAGR of 6.1%.
Alcoholic hepatitis (AH) is liver inflammation caused by drinking alcohol. It is identified by the rapid onset of jaundice, malaise, anorexia, tender hepatomegaly, and systemic inflammatory response syndrome (SIRS) features. Alcoholic hepatitis most likely occurs in individuals who drink heavily over many years. Patients with alcoholic hepatitis are systemically ill with a high risk of nutritional deficiency, acute kidney injury (AKI), infection, and development of multiorgan failure (MOF) syndrome. For instance, approximately two-thirds of the US adult population drinks alcohol each year, and 7.4% report heavy drinking and meet the criteria for alcoholism. However, only a minority of heavy drinkers will develop alcoholic liver disease (ALD), likely due to environmental and genetic factors. To enhance clinical outcomes for patients with severe alcoholic hepatitis, it is crucial to accurately identify possible complications and understand the basic mechanisms underlying alcohol-induced liver damage.
FutureWise Market Research has published a report that provides an insightful analysis of Alcoholic Hepatitis Therapeutics Market trends affecting overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Alcoholic-Hepatitis-Therapeutics/11007
Alcoholic Hepatitis Therapeutics Market Segmentation:
By Drug Type
- Monoclonal antibodies
- Caspase protease inhibitor
- Corticosteroids
- Hemorheologic agents
- Anabolic steroids
- Hepatotropic hormones
- Sulfhydryl agents
- Other Drug Types
By Application
- Mild Disease
- Severe Disease
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in the Alcoholic Hepatitis Therapeutics Market:
- Alkermes Inc.
- Alfact Innovation
- Conatus Pharmaceuticals Inc.
- Dainippon sumitomo pharma Co. ltd.
- Generon Corporation Ltd.
- Immuron limited
- Lupin Laboratories Ltd.
- Intercept Pharmaceuticals Inc.
- Teva Pharmaceuticals Ltd.
- Sanofi-Aventis
- Siesta Pharmaceuticals
- Gilead Sciences Inc
- ABBVIE Inc
- Novartis
- Roche
Buy now the latest version of this report:
https://www.futurewiseresearch.com/checkout.aspx?ReportId=11007&license=single
**Objectives of this Study: **
- To provide a comprehensive analysis of the Alcoholic Hepatitis Therapeutics Market By Drug Type, By Application, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Related market:
Some of the other related markets that you might be interested in are listed as below:
Alcohol Addiction Therapeutics Market
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
FutureWise Research
Contact Person: Vinay Thaploo.
Email: sales@futurewiseresearch.com
Contact Number: Asia: +91 8605575209 | USA: +1 3477094931
Website: www.futurewiseresearch.com
